TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04743193

Intervention type: OTHER
Intervention: 2.5 %sevoflurane
Description: for 35 patients after reaching 1 MAK level with 4 lt / min fresh gas flow and 2,5% sevoflurane concentration in the initial phase, maintenance of anesthesia will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 minimum alveolar concentration

Intervention type: OTHER
Intervention: 8% sevoflurane low flow anesthesia
Description: For 35 patients after reaching 1 (MAC) level with 1 lt / min fresh gas flow and 8% sevoflurane concentration in the initial phase, maintenance of anesthesia will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration, targeting 1 MAC. .
Study: NCT06625073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: A starting dose of empagliflozin 10 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Participating subjects will remain at this dose for the whole study duration of 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A starting dose of empagliflozin 10 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Participating subjects will remain at this dose for the whole study duration of 12 months.
Study: NCT06624605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large Language Model-generated Plain Language Summary of Ophthalmology notes
Description: Prospective, randomized Quality Improvement study with real-world implementation of Large Language Model-generated Plain Language Summaries of Ophthalmology notes.
Study: NCT06684964

Intervention type: OTHER
Intervention: asciminib
Description: This is an observational study. There is no treatment allocation. The decision to initiate asciminib will be based solely on clinical judgement.
Study: NCT05473663

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation
Description: Genicular nerve RFA is a standard outpatient procedure using fluoroscopic guidance to ensure accurate placement of the radiofrequency cannula. After placement of the radiofrequency cannula, nerve stimulation is performed to confirm proper position and ensure that the cannula is not too close to motor fibers. One mL of 2% lidocaine is placed at each of the cannulas. The RFA treatment is then proceeded by rhizotomizing each genicular nerve at 80°C for 90 seconds with a 15-second ramp-up.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Is performed identically to the active treatment but without the application of the RFA current
Study: NCT06491238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light Intensity Exercise
Description: 12 weeks light intensity strength and endurance NeuroWell exercise program, specifically developed for individuals with neurological disorders or injuries. Participants have the intensity goals descripted in the experimental arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Exercise
Description: 12 weeks moderate intensity strength and endurance NeuroWell exercise program, specifically developed for individuals with neurological disorders or injuries. Participants have the intensity goals descripted in the experimental arm.
Study: NCT05807958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin Prick Automated Test
Description: A skin prick automated test will be performed in each participant.
Study: NCT06709391

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fusion surgery
Description: After anaesthesia, the surgical area is identified through intraoperative fluoroscopy. After sterile draping, incision is made through skin and subcutaneous fat. Dissection is performed bilaterally down to the facet joints and transverse processes. Intraoperative fluoroscopy or computed tomography is performed to verify the surgical level. When the dissection is complete, randomization takes place.~Randomization to fusion (active treatment):~Pedicle screws are placed. Interbody cages may be used. Fluoroscopy or intraoperative computed tomography with or without intraoperative navigation is performed for correct implant positioning. Decortication is performed in the surgical area, and the cartilage in the facet joints is partially removed to allow fusion. Local bone graft is used and placed in the surgical area. Rods are placed in the screws and the fixation system is locked. Local anaesthesia is given in the surgical area. Fascia, subcutaneous tissue, and skin is sutured.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Non-fusion surgery
Description: After anaesthesia, the surgical area is identified through intraoperative fluoroscopy. After sterile draping, incision is made through skin and subcutaneous fat. Dissection is performed bilaterally down to the facet joints and transverse processes. Intraoperative fluoroscopy or computed tomography is performed to verify the surgical level. When the dissection is complete, randomization takes place.~Randomization to non-fusion surgery (control):~No implants are placed. No decortication is performed. The facet joints are left intact. Local anaesthesia is given in the surgical area. Fascia, subcutaneous tissue and skin is sutured.
Study: NCT06716606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab will be administered.
Study: NCT06737809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IP Plasmafit® Revision cup (and stem) system
Description: Revision total hip arthroplasty (THA) due to periprosthetic joint infection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IP Plasmafit® Revision cup (and stem) system
Description: Revision total hip arthroplasty (THA) due to periprosthetic joint infection
Study: NCT06742268

Intervention type: OTHER
Intervention: Single vision spectacles
Description: Other interventions for myopia treatment, except for glasses, will not be provided.

Intervention type: OTHER
Intervention: Single vision spectacles
Description: Other interventions for myopia treatment, except for glasses, will not be provided.
Study: NCT06751563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Text Messages and Produce Box Delivery
Description: Participants will receive a produce box delivered weekly to the participants home customized based on the participants cooking preferences and household size. Participants will also receive a daily text message aimed to support a healthy diet and lifestyle. These texts will include information to build participants' knowledge and skills for healthy eating. The participants will also include weekly goals that focus on eating a healthy diet. Participants will receive automated, personalized feedback via text messages based on participant goal attainment and daily responses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Text Message Program and Produce Voucher
Description: Participants will receive a weekly produce voucher redeemable at a local market vendor for fresh produce of the participant's choice. Participants will also receive a daily text message aimed to support a healthy diet and lifestyle. These texts will include information to build participants' knowledge and skills for healthy eating. The participants will also include weekly goals that focus on eating a healthy diet. Participants will receive automated, personalized feedback via text messages based on goal attainment and daily responses.
Study: NCT06749613

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: digestive enzymes
Description: A jar or single-dose sachets containing the digestive enzymes in the form of powder will be provided to each patient at the study entry. Patients will be instructed to use the powder formulation according to manufacturer instructions and according to the meals that they consume per day, for 1 month. Participants will be asked to return the jar or the single dose sachets with the remaining product to assess compliance either by weighting the jar or by counting the number of single-dose sachets returned. To reduce the placebo effect, patients will be misinformed that half will take a placebo formulation, randomly. Participants will be asked to return the jar or the single-dose sachets with the remaining product to assess compliance either by weighting the jar or by counting the number of single-dose sachets returned.
Study: NCT06749951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for insomnia (CBT-I)
Description: Five 60-90 minutes weekly sessions delivered by an appropriately trained cardiac nurse at a cardiology department. The CBT-I intervention will follow a manualized treatment protocol developed by Espie and colleagues (Espie et al. 2001, 2007, 2008) and evaluated in a number of published RCTs using CBT-I. The key components of this intervention include sleep hygiene advice, stimulus control, sleep restriction, relaxation training, and cognitive restructuring.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene Advice
Description: Sleep well is a 16-page written brochure developed by the Directorate of Health in Norway for dissemination to patients with sleep problems including insomnia. It covers general sleep hygiene advice (setting a regular bed-time, avoiding stimulants, alcohol and exercise in the evening, sleeping in a quiet bedroom, advice of practicing relaxation technique and postpone worries).
Study: NCT06761417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone liposome
Description: Mitoxantrone liposome: 16 mg/m\^2, d1; Each 21-day cycle was used for a total of 4-6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m\^2, d1-14, bid; Each 21-day cycle was used for a total of 4-6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib: according to patient weight: 8mg/ day in patients \<35kg; 10mg/ day for patients with 35kg≤ patient weight ≤50kg; 12mg/ day for patients \> 50kg; d1-14; Each 21-day cycle was used for a total of 4-6 cycles.
Study: NCT06765434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music ( Dmitri Shostakovich's Jazz Waltz Suite)
Description: Music

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music( Personalized music)
Description: Music
Study: NCT06766513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actimetry
Description: actimetry will be performed continuously during these 104 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actimetry
Description: actimetry will be performed continuously during these 104 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subjective assessments
Description: The subjective assessments of the patient's awake/sleep state will be collected every 2 hours during the night and at least 3 times during the day, for a total of at least 8 assessments per 24-hour period, over a duration of 104 consecutive hours (slightly more than 4 days, starting at midnight and ending at 8 :00 AM, to cover 4 full days and 4 full nights).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subjective assessments
Description: The subjective assessments of the patient's awake/sleep state will be collected every 2 hours during the night and at least 3 times during the day, for a total of at least 8 assessments per 24-hour period, over a duration of 104 consecutive hours (slightly more than 4 days, starting at midnight and ending at 8 :00 AM, to cover 4 full days and 4 full nights).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: MOCA : Montreal Cognitive Assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: MOCA : Montreal Cognitive Assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: SF-36 The Short Form (36)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: SF-36 The Short Form (36)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: CRS-R (Coma Recovery Scale-Revised)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: CRS-R (Coma Recovery Scale-Revised)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: GOSE (Glasgow Outcome Scale-Extended)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: GOSE (Glasgow Outcome Scale-Extended)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: GCS (Glasgow Coma Scale)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: GCS (Glasgow Coma Scale)
Study: NCT06766461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double dosing of beta-lactam antibiotic
Description: This arm will receive double dosing of beta-lactam antibiotics for the first 48 hours after inclusion.
Study: NCT06764927

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cryoprecipitate Intercept Fibrinogen Complex (IFC)
Description: INTERCEPT Fibrinogen Complex is a pathogen-reduced cryoprecipitated fibrinogen complex derived from human plasma. It contains fibrinogen, Factor XIII, and von Willebrand factor to achieve stable clot formation and restore hemostasis1. Recently approved by the US Food and Drug Administration, it is used for the treatment of bleeding associated with fibrinogen deficiency.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cryoprecipitate Antihemophilic Factor (AHF)
Description: Cryoprecipitate Antihemophilic Factor (AHF), also known as cryo, is a frozen blood product prepared from blood plasma. It is used for fibrinogen supplementation, particularly for hypofibrinogenemia fibrinogen, anemia associated with bleeding or congenital deficiency.
Study: NCT06769074

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: PRP injection into the midurethra and its instillation into urinary bladder
Study: NCT06765083

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: POCUS of the hip
Description: POCUS of the hip (proximal femur) by the (resident) emergency physician, prior to radiograph imaging.
Study: NCT06766045

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Ultrasound
Description: Diaphragmatic ultrasound was performed bedside in the ICU with supine position. Diaphragmatic thickness was measured by placing the ultrasound on 8th-10th intercostal space between anterior and mid-axillary line with marker at 12 o'clock. B-mode ultrasound was used to measure the distance between thoracic and abdominal diaphragm which resulted in the diaphragmatic thickness at inspiration (DTi) and diaphragmatic thickness at expiration (DTe).~The ultrasound was then placed on the subcostal area between anterior and mid-axillary line with marker at 12 o'clock to observe the diaphragmatic motion on each side. Measurement of diaphragmatic excursion as well as recording and evaluation of diaphragmatic sliding and motion were performed during both inspiration and expiration using M-mode.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluoroscopy
Description: Fluoroscopy test was conducted in cathlab with supine position and anteroposterior (AP) projection for at least 5 breathing cycles. The fluoroscopy recording was then expertised and interpreted by the pediatric cardiologist in charge.
Study: NCT06765460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical prescription of exercise
Description: MPE consists of dedicating a specific time to establish a specific and individualized exercise plan for the patient, with the premises of fully assessing their physical fitness, motivation, adaptability to change and the possibility of exercising within their social environment, as well as the achievement of specific objectives within an agreed follow-up period

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Advice
Description: HA consists of providing the patient with information and motivation in line with general international recommendations to try to increase PA levels in their daily life. This advice can be given in a short period of time (up to three minutes) during any medical consultation
Study: NCT06764862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK44459 dose 1
Description: HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK44459 dose 2
Description: HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
Study: NCT06768294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib 4 MG Oral Tablet
Description: Baricitinib is a JAK1/JAK2 inhibitor approved for use in Rheumatoid Arthritis. It is under investigation for use in several inflammatory diseases, including Psoriasis and Psoriatic Arthritis, Atopic Dermatitis, Inflammatory Bowel Disease and Systemic Lupus Erythematosus, with encouraging results. As IL-6 plays a central role in CPPD inflammatory process, a broad spectrum of interleukins and other proinflammatory proteins (including interferons) could be involved. A drug that acts by blocking more than one proinflammatory cytokine could be a promising treatment for a multifaceted disease such as CPPD.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Methylprednisolone (Corticosteroid)
Description: The initial dosage of methylprednisolone may vary depending on the entity of inflammation and the patient's comorbidities. Usually in CPPD a short-term administration of methylprednisolone starts with 16 mg per day after breakfast decreasing the initial dosage in small decrements at appropriate time intervals until discontinuation, in about 2 weeks. Methylprednisolone will be given in combination with gastroprotective agents such as proton pump inhibitors.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Colchicine 1 MG Oral Tablet
Description: 1 or ½ tablet (depending on individual tolerance) daily after breakfast

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Hydroxychloroquine 200 mg
Description: 1 tablet daily after lunch

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Methotrexate + Folic Acid
Description: MTX 2.5 mg tablets, from 2 to 4 tablets (5-10mg), depending on disease severity, to be administered once weekly after dinner, always in the same day of the week. One tablet of folic acid (folina 5 mg) will be administered the day after MTX administration, after breakfast, to reduce and prevent the common side effects of MTX.
Study: NCT06767930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand and Arm Bimanual Intensive Therapy Including Lower Extremities
Description: The HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) program is an intensive rehabilitation therapy designed to improve motor functions and promote functional independence. Participants in this arm will engage in 6.5 hours of structured activities per day for two weeks (10 days). The therapy focuses on bimanual coordination combined with constant stimulation of the trunk and/or lower extremities, using task-oriented exercises tailored to individual goals. Each participant will be supported by one or two therapists and supervised by a trained team to ensure the program is delivered effectively and safely. The therapy emphasizes engaging, play-based activities to maximize motivation and active participation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional intervention
Description: Participants in the control group will continue their usual care, which includes conventional physical and occupational therapy, for a duration of two weeks. They will follow their regular therapy schedules without any changes to their routines or treatment habits. This approach ensures that the control group reflects standard rehabilitation practices, allowing for a direct comparison with the intervention group.
Study: NCT06769243

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Transcranial Magnetic Stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain. It is primarily used to treat OCD, particularly in patients who have not responded well to traditional treatments such as medications or psychotherapy. The most common target is the supplementary motor area (SMA), which has an indirect connection with the Cortico-Striato-Thalamo-Cortical (CSTC) pathway, known to be hyperactive in OCD.~Another option to target the CSTC pathway is deep TMS, although it is not available in most advanced centers. The magnetic pulses from TMS stimulate or inhibit brain activity in the targeted area, which is believed to help reset or correct neural activity patterns associated with OCD and other psychiatric disorders.~TMS represents an alternative treatment for those struggling with OCD, offering a non-invasive approach with relatively few side effects and significant potential benefits.
Study: NCT06767527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: AK112 via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-Paclitaxel 100mg/m2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-Paclitaxel 100mg/m2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo via IV infusion
Study: NCT06765265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg/day
Description: Rosuvastatin 20 mg / Day for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 40 mg
Description: Atorvastatin 40mg / Day for 24 weeks